Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Trial results show promising insights into the potential of retatrutide for addressing obesity and various weight-related conditions: In patients with type 2 diabetes (T2D) and obesity, subcutaneous administration of retatrutide for 12 weeks resulted in reductions in body weight of up to 8.96 kg with a safety and tolerability profile similar to other incretins (weight loss peptides)
A time point is considered as on treatment if any dose of trial product has been administered within the previous 14 days
Oral semaglutide formulations exist but use different absorption enhancers (specifically SNAC, or sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable gastrointestinal absorption
A 31-gauge needle works for leaner individuals but flows more slowly
Klow stack or Klow blend
convenience of oral dosing but slightly reduced efficacy for weight loss
US$ 24.37
US$ 29.13
US$ 25.55
US$ 22.23
